Literature DB >> 10147352

Quality-of-life assessment in patients with headache.

G D Solomon1.   

Abstract

Although headache is the most common pain complaint seen by primary care physicians, the measurement of quality of life in patients with headache is in its earliest stages. Most of the research has been published within the past 2 years, much of it only in abstract form. Quality-of-life data derived from the Medical Outcomes Study instrument (SF-20) demonstrate that chronic headache disorders are associated with significant limitations in all 6 health categories of patient well-being and functioning. The outcomes profile for each of the common benign headache disorders appear to be unique for the specific headache diagnosis. Migraine is primarily associated with an impairment in role (work) functioning. Chronic tension-type headache is associated with a marked impairment in mental health and a generalised impairment in functioning. Cluster headache is associated with the greatest amount of pain, but with little impairment in physical functioning. The economic toll of recurrent headache is considerable. Lost productivity in the US due to migraine is estimated at $US6.5 to 17.2 billion per year. Chronic headache disorders cause significantly more morbidity, impairment of function, and economic loss than has previously been recognised.

Entities:  

Mesh:

Year:  1994        PMID: 10147352     DOI: 10.2165/00019053-199406010-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  13 in total

1.  Quality-of-life evaluation in diabetes.

Authors:  C Eiser; J E Tooke
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

2.  Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors.

Authors:  W F Stewart; R B Lipton; D D Celentano; M L Reed
Journal:  JAMA       Date:  1992-01-01       Impact factor: 56.272

3.  Healthcare resource and lost labour costs of migraine headache in the US.

Authors:  J T Osterhaus; D L Gutterman; J R Plachetka
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

4.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

5.  The Henry Ford Hospital Headache Disability Inventory (HDI).

Authors:  G P Jacobson; N M Ramadan; S K Aggarwal; C W Newman
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

6.  Does quality of life differ among headache diagnoses? Analysis using the medical outcomes study instrument.

Authors:  G D Solomon; F G Skobieranda; L A Gragg
Journal:  Headache       Date:  1994-03       Impact factor: 5.887

7.  The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

Authors:  C A McHorney; J E Ware; A E Raczek
Journal:  Med Care       Date:  1993-03       Impact factor: 2.983

8.  A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache.

Authors:  W Pryse-Phillips; H Findlay; P Tugwell; J Edmeads; T J Murray; R F Nelson
Journal:  Can J Neurol Sci       Date:  1992-08       Impact factor: 2.104

9.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study.

Authors:  A L Stewart; S Greenfield; R D Hays; K Wells; W H Rogers; S D Berry; E A McGlynn; J E Ware
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

10.  Quality of life and well-being of headache patients: measurement by the medical outcomes study instrument.

Authors:  G D Solomon; F G Skobieranda; L A Gragg
Journal:  Headache       Date:  1993 Jul-Aug       Impact factor: 5.887

View more
  4 in total

Review 1.  Sumatriptan. A pharmacoeconomic review of its use in migraine.

Authors:  A J Coukell; H M Lamb
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

2.  A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity.

Authors:  P Cortelli; C Dahlöf; J Bouchard; J Heywood; J P Jansen; S Pham; J Hirsch; J Adams; D W Miller
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

Review 3.  Oral serotonin receptor agonists: a review of their cost effectiveness in migraine.

Authors:  Jennifer H Lofland; David B Nash
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Reversible dyscognition in patients with a unilateral, middle fossa arachnoid cyst revealed by using a laptop based neuropsychological test battery (CANTAB).

Authors:  Johan Torgersen; Christian Helland; Hans Flaatten; Knut Wester
Journal:  J Neurol       Date:  2010-07-04       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.